Alliance Pharma plc’s (APH) “Buy” Rating Reaffirmed at FinnCap
Alliance Pharma plc (LON:APH)‘s stock had its “buy” rating reaffirmed by equities research analysts at FinnCap in a research note issued on Thursday. They currently have a GBX 58 ($0.75) target price on the stock. FinnCap’s price target would suggest a potential upside of 9.95% from the company’s current price.
Other equities analysts have also recently issued research reports about the company. Investec started coverage on Alliance Pharma plc in a research note on Wednesday. They issued a “buy” rating and a GBX 59 ($0.76) price target on the stock. Numis Securities Ltd reissued a “buy” rating and issued a GBX 60 ($0.77) price target on shares of Alliance Pharma plc in a research note on Wednesday. Finally, N+1 Singer reissued a “not rated” rating on shares of Alliance Pharma plc in a research note on Wednesday.
Alliance Pharma plc (LON:APH) opened at 52.75 on Thursday. The stock’s market capitalization is GBX 249.36 million. Alliance Pharma plc has a 12-month low of GBX 41.33 and a 12-month high of GBX 57.56. The firm has a 50-day moving average of GBX 52.51 and a 200-day moving average of GBX 50.61.
About Alliance Pharma plc
Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.
Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with MarketBeat.com's FREE daily email newsletter.